Gluten Sensibility in Elite Athletes

Intestinal Diseases Clinical Trial

— GLUTHEALTH  

Official title:

Gluten Sensibility in Elite Athletes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03101410
• Other study ID #: CHU-308
• Secondary ID: 2016-A00356-45
• Status: Completed
• Phase: N/A
• Start date: April 1, 2017
• Est. completion date: March 21, 2018

Study information

• Verified date: June 2018
• Source: University Hospital, Clermont-Ferrand
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical project aims to study the relationship between gluten consumption and its impact on digestive comfort, quality of life and performance of non-celiac athletes practicing an intensive physical activity..

Description:

Gluten is a protein network that results from both, the hydration and the kneading of storage proteins contained in the endosperm of certain cereals. Gluten is particularly found in bread products but it is also found in many processed products because of its physicochemical properties (binding, swelling properties ...). This omnipresence is now blamed, and a growing percentage of the population reports "intolerance" to gluten. This gluten sensitivity hypothesis is frequently associated with intestinal disorders (irritable bowel syndrome, bloating, abdominal pain, chronic diarrhea, constipation) but also with headache, fatigue, muscle and joint aches, bone fragility, migraine, eczema, depression, anxiety .... This assumption has led to the adoption of increasingly frequent gluten-free diets among the general population, without medical justification.

Among the population, athletes are particularly concerned due to a higher prevalence of anaphylaxis dependent on the combination of physical exercise and food intake (Maulitz and Kidd syndrome). This syndrome is notably reported with consumption of cereals in particular wheat (bread, pasta). However, these conditions are poorly described with regards to gluten and scientific investigations are required to rationally characterize the benefits of gluten-free diets for elite athletes.

Therefore, this clinical project aims to study the relationship between gluten consumption and its impact on digestive comfort, quality of life and performance of non-celiac athletes practicing an intensive physical activity.

All the participants will give freely their written informed consent before their selection in the study.

Information on physical activities, demographics, anthropometrics, vital signs, relevant medical history and concomitant medication, dietary habits, usual dietary intake and nutritional supplements will be collected. All inclusion and exclusion criteria will be checked by the investigator or co-investigator.

Selected participants will be randomly allocated to treatment group (gluten or gluten free). Couple from the same family will be randomised in the same group.

After 2 months, all subjects will have the diet without gluten.

All recruited volunteers will be asked to replace their bread and pasta intake by study products (pasta and white bread with or without gluten), maintain their usual dietary habits and continue their normal physical habits.

Each 2 months, volunteers will have a physical performance assessment and will provide a blood and faeces samples. All volunteers will complete a follow-up questionnaire to obtain information about any changes in medication use, disease etc. Each week, all subjects will complete a questionnaire related to digestive function :Food Benefits Assessment (FBA)).

At the beginning and 2 months, usual dietary intakes will be estimated by means of a 3- days food records.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: March 21, 2018
• Est. primary completion date: March 21, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female trained >7h/week or more of 5 training/week

• Member of a sports federation or medical certificate fewer 3 months

• VO2 max estimated >125% of the theoretical value

• Regular consumption of gluten under different products

• Healthy (apparently free of diseases) and without any medical treatment

• Without digestive diseases and non-coeliac disease

• Affiliated to National Health Insurance

• Having normal capacity of training to enter in the study procedures

• Having provided her written informed consent

Exclusion Criteria:

• Medicals or surgical histories, evaluated non compatible by the investigator

• Diseases known

• Antibiotherapy 2 months before the study

• Gluten-free diet

• Individual unable to give informed consent or refusing to sign informed consent

• Being in exclusion on the National Volunteers Data file or refusing to be registered on the National Volunteers Data file

• Currently participating or who having got 4500€ in this year before to have participating in another clinical trial

Related Conditions & MeSH terms

• Gluten-sensitive
• Intestinal Diseases

Intervention

Behavioral:
• Gluten
Selected participants will be randomly allocated to treatment group (gluten or gluten free).
• Gluten free
Selected participants will be randomly allocated to treatment group (gluten or gluten free).

Locations

Country	Name	City	State
France	CHU Clermont-Ferrand	Clermont-Ferrand

Sponsors (4)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand	Centre de Recherche en Nutrition Humaine d'Auvergne, Institut Carnot Qualiment, Institut National de la Recherche Agronomique

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Food Benefits Assessment (FBA)		at the beginning of the study, at 2 month and 4 month
Secondary	Physicals performances assessment : 3000m running performance		at the beginning of the study, at 2 month and 4 month
Secondary	Microbiota composition analysis on faeces samples	Microbiote composition will be measured by qPCR, targeting 16S gene	at the beginning of the study, at 2 month and 4 month
Secondary	Changes in body composition measured by bioelectrical impedance		at the beginning of the study, at 2 month and 4 month
Secondary	Qualities life index for digestive disorders modified (GIQLI assessment modified)		at the beginning of the study, at 2 month and 4 month
Secondary	Inflammatory cytokines		at the beginning of the study, at 2 month and 4 month
Secondary	Bone and joint cytokines		at the beginning of the study, at 2 month and 4 month
Secondary	Immune function from lymphocytes	Their reactivity will be studied in the presence of three different forms of gliadins: native, deaminated and hydrolysed	at the beginning of the study, at 2 month and 4 month